Literature DB >> 12522442

Adenoviral vectors: systemic delivery and tumor targeting.

Nicola K Green1, Leonard W Seymour.   

Abstract

The development of a targeted adenoviral vector, which can be delivered systemically, is one of the major challenges facing cancer gene therapy. The virus is readily cleared from the bloodstream, can be neutralised by pre-existing antibodies, and has a permissive cellular tropism. Clinical studies using the ONYX virus have shown limited efficacy, but there are several hurdles to overcome to achieve an effective tumor-specific systemic therapy. In this review, we have summarized the various strategies used to overcome the limitations of adenoviral-mediated gene delivery.

Entities:  

Mesh：

Year:  2002        PMID： 12522442     DOI： 10.1038/sj.cgt.7700541

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


  14 in total

Review 1.  Pancreatic cancer from bench to bedside: molecular pathways and treatment options.

Authors:  Christoforos Kosmidis; Konstantinos Sapalidis; Efstathios Kotidis; Nikolaos Mixalopoulos; Paul Zarogoulidis; Drosos Tsavlis; Sofia Baka; Yan-Gao Man; John Kanellos
Journal:  Ann Transl Med       Date:  2016-05

2.  The effect of fiber truncations on the stability of adenovirus type 5.

Authors:  Grit Kupgan; Danielle C Hentges; Nathan J Muschinske; William D Picking; Wendy L Picking; Joshua D Ramsey
Journal:  Mol Biotechnol       Date:  2014-11       Impact factor: 2.695

3.  Enhanced CRAd activity using enhancer motifs driven by a nucleosome positioning sequence.

Authors:  Soraya Bravo; Felipe Núñez; Fernando Cruzat; Eduardo G Cafferata; Giancarlo V De Ferrari; Martín Montecino; Osvaldo L Podhajcer
Journal:  Mol Ther       Date:  2013-05-28       Impact factor: 11.454

4.  Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma.

Authors:  Gernot W Wolkersdörfer; Christian Thiede; Rainer Fischer; Gerhard Ehninger; Cornelie Haag
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

5.  Magnetic nanoparticles as a new approach to improve the efficacy of gene therapy against differentiated human uterine fibroid cells and tumor-initiating stem cells.

Authors:  Shahinaz Mahmood Shalaby; Mostafa K Khater; Aymara Mas Perucho; Sara A Mohamed; Inas Helwa; Archana Laknaur; Iryna Lebedyeva; Yutao Liu; Michael P Diamond; Ayman A Al-Hendy
Journal:  Fertil Steril       Date:  2016-03-25       Impact factor: 7.329

6.  Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery.

Authors:  Prasad S Adusumilli; Brendon M Stiles; Mei-Ki Chan; David P Eisenberg; Zhenkun Yu; Stephen F Stanziale; Rumana Huq; Richard J Wong; Valerie W Rusch; Yuman Fong
Journal:  FASEB J       Date:  2006-02-08       Impact factor: 5.191

Review 7.  Viro-immune therapy: A new strategy for treatment of pancreatic cancer.

Authors:  Andrea Marie Ibrahim; Yao-He Wang
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

8.  Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution.

Authors:  Xiong Li; Youhong Liu; Yong Tang; Phipps Roger; Meei-Huey Jeng; Chinghai Kao
Journal:  J Gene Med       Date:  2010-06       Impact factor: 4.152

Review 9.  Bacteriophage-derived vectors for targeted cancer gene therapy.

Authors:  Md Zahidul Islam Pranjol; Amin Hajitou
Journal:  Viruses       Date:  2015-01-19       Impact factor: 5.048

10.  Tumor-targeted delivery of biologically active TRAIL protein.

Authors:  H-Y Zhang; J-H Man; B Liang; T Zhou; C-H Wang; T Li; H-Y Li; W-H Li; B-F Jin; P-J Zhang; J Zhao; X Pan; K He; W-L Gong; X-M Zhang; A-L Li
Journal:  Cancer Gene Ther       Date:  2010-01-15       Impact factor: 5.987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.